Parkinson's Disease Clinical Trial
Official title:
Comparison of Constant Current to Constant Voltage Stimulation in Subthalamic DBS for Parkinson's Disease
HYPOTHESIS: Constant current stimulation for STN DBS will allow better and more stable
control of Parkinson's disease symptoms than constant voltage stimulation.
Subthalamic nucleus (STN) deep brain stimulation (DBS) is an established therapy for
advanced Parkinson's disease (PD). Two types of implantable pulse generators (IPGs) are
available, differing on whether voltage or electrical current is controlled. Constant
current IPGs provide a specific electrical current and will automatically adjust the voltage
depending on the impedance, while the current applied by constant voltage IPGs will depend
on the tissue impedance that may change over time. No study has compared the clinical
differences of these two electronic modalities.
Deep brain stimulation (DBS) is an established therapy for neurological and psychiatric
disorders, being one of the most important therapies in functional neurosurgery to date.
Class I evidence shows that subthalamic nucleus stimulation (STN) for Parkinson's disease
(PD) is more effective than the best medical therapy (1,2). Globus pallidus internus
stimulation for primary dystonia has an improvement rate of up to 70%(4) and is considered
the main surgical treatment for this pathology. Symptom improvement in essential tremor is
well documented. Pain, epilepsy, psychiatric disorders such as Tourette syndrome, obsessive
- compulsive disorder and depression are promising applications of DBS. Obesity, memory
improvement, aggressiveness, drug addiction, minimal conscious state and hypertension are
areas of continuing investigation as potential applications of DBS.
The clinical effects of DBS result from the delivery of electrical charge to brain tissue.
The way this electrical charge is delivered depends on the electronics of implantable pulse
generators (IPGs). IPGs apply pulses of electrical stimulation in which voltage or current
increases from zero to a maximum value for a period of time (order of tens of microseconds)
and then returns to zero.
There are two types IPGs , differing on whether voltage or electrical current is controlled
(3).
1. Constant - voltage IPGs: in this type of IPG there is control over the maximum voltage
associated with each pulse. The maximum current will vary depending on the impedance. A
specific voltage is programmed. The amount of electrical current delivered with a
constant voltage depends on the impedance of the tissue and the electrodes. Thus, the
voltage will not indicate how much electrical current is given; the resistance will
determine this parameter.
2. Constant - current IPGs: provide a specific electrical current and will automatically
adjust the voltage depending on the impedance. The strength of stimulation will remain
the same regardless of changes in the impedance. The difference in impedances on each
electrode and the intersubject variability in impedances will not alter the electrical
current by modifying the voltage.
Until fairly recently, only constant voltage IPG's have been available for use. A newer
generation of IPG's have been available for more than a year that can provide either
constant voltage or constant current according to physician and patient preference. There is
no evidence yet to support the preferential use of one modality over the other.
IMPORTANCE OF THE STUDY Following DBS electrode implantation, the impedances within the same
patient can vary widely. Surgical implantation changes tissue impedance, being usually
higher immediately after surgery. In this case the patient will require higher electrical
currents. After the initial tissue reaction subsides, the reduction of impedance will
generate an increase of the charge density. For this reason it is commonplace to wait at
least 2 weeks after electrode implantation before programming the IPG.
Furthermore, different contacts on the same DBS lead can have widely varying impedances.
Effects or side effects associated with stimulation of one electrode contact often cannot be
applied to a different contact on the same DBS lead in the same patient because the
impedances may differ.
The range of impedances that can be measured will depend on the choice of voltage. In some
patients, the voltage used therapeutically may not be enough to allow an accurate measure of
the impedances, causing confusion regarding the structural and electrical integrity of the
IPG.
For all the above mentioned factors, the clinical results in patients with constant -
voltage IPGs will depend on the experience of the operator to deal with the different
aspects related to tissue and electrode impedances to achieve the desired current. The
electronic properties of constant - current IPGs allows the system to make voltage
adjustments in order to maintain the desired current and the subsequent clinical effect.
This has been the theoretical background for the development of constant current IPG's;
whether or not this theory is true in practice is the subject of this study.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |